Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19, 2025. Under the terms of the agreement, Paratek will acquire Optinose, including its approved product XHANCE (fluticasone propionate), an innovative drug-device combination for the treatment of chronic rhinosinusitis (CRS) with or without nasal polyps.
Transaction Details
The transaction is valued at up to $330 million. Paratek will acquire all of Optinose’s outstanding shares for $9 per share in cash, representing a 50% premium to Optinose’s closing trading price on March 19, 2025. Additionally, Paratek will pay $5 per share in contingent value rights (CVRs) if certain net revenue milestones are achieved by XHANCE. The deal is expected to close as early as mid-2025, subject to customary closing conditions.
Post-Merger Plans
Upon completion of the merger, Paratek will leverage its expanded commercial infrastructure to accelerate awareness and adoption of XHANCE in the grassroots market. Optinose’s common stock will be delisted from the NASDAQ Global Market following the transaction.-Fineline Info & Tech
Leave a Reply